The largest database of trusted experimental protocols

Sapien devices

Manufactured by Edwards Lifesciences
Sourced in United States

The SAPIEN devices are a line of transcatheter aortic valve replacement (TAVR) products developed by Edwards Lifesciences. The core function of the SAPIEN devices is to provide minimally invasive treatment options for patients with severe aortic stenosis.

Automatically generated - may contain errors

Lab products found in correlation

2 protocols using sapien devices

1

Transcatheter Aortic Valve Replacement Procedure

Check if the same lab product or an alternative is used in the 5 most similar protocols
All TAVR procedures were performed using either the SAPIEN devices (Edwards Lifesciences, Irvine, California) or the CoreValve Evolut R/PRO devices (Medtronic, Minneapolis, Minnesota). Optimal type and size of transcatheter heart valve were determined using preprocedural multidetector CT measurements evaluated with 3mensio Structural Heart software (3mensio Medical Imaging BV, Bilthoven, The Netherlands). Pre-dilatation and post-dilatation were left to the physician’s discretion. During the TAVR procedure, unfractionated heparin was administered to achieve an activated clotting time of 250–300 s. Closure of the vascular access was usually performed using two Perclose ProGlide™ vascular closure systems (Abbott Laboratories, Chicago, IL, USA).
+ Open protocol
+ Expand
2

Transapical Transcatheter Aortic Procedures

Check if the same lab product or an alternative is used in the 5 most similar protocols
From March 2015 to April 2022, all patients affected by severe aortic stenosis undergoing transapical transcatheter aortic procedures at the Division of Cardiac Surgery of University Hospital in Verona were enrolled. The balloon expandable SAPIEN devices (Edwards Lifesciences, Irvine, CA, USA) were used for both TAVR and Valve-in-Valve (ViV) procedures in the aortic position. The interdisciplinary Heart-Team selected patients for the TA approach according to the latest European and American guidelines for the management of valvular heart diseases [1 (link),2 (link)]. The appropriate prosthetic size was determined on computed tomography findings. All patients underwent general anesthesia, and all the procedures were carried out in the catheterization laboratory by an expert cardiac surgeon together with a proficient interventional cardiologist that took care of the actual valve positioning and deployment.
Pre-procedural, intra-procedural, and post-procedural data were retrospectively collected in a dedicated and anonymized database. Follow-up clinical data were gathered by querying the Electronic Clinical Chart (retrieving data from the Regional Health Database) or the patients. The clinical follow-up was complete for 100% of the patients. Informed consent was obtained from all of the patients.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!